Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 37 to 50 years by 2025.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
Restore CFTR FunctionCompleted with results Location: USA
VX-661 alone and in combination with ivacaftor in people with cystic fibrosis , protocol number Vertex VX11-661-101
This study is taking place at multiple care centers across the U.S. It looked at the safety and effectiveness of VX-661 alone and in combination with ivacaftor, as well as how the drug works in the body, in people with CF.
Age:
18 Years and Older
Mutation(s):
Two copies F508del
FEV1% Predicted:
40 to 90%
Number of Visits:
9
Length of Participation:
84 days
Study of VX-661 combined with ivacaftor in adults with cystic fibrosis , protocol number NCT02070744 VERTEX VX-661-103
This study evaluated the safety and the best way to dose VX-661 in combination with ivacaftor. This study was for adults with CF who have two copies of the F508del CFTR mutation.
8
20 weeks
Restore CFTR FunctionClosed to enrollment Location: USA
Phase 3 study of VX-661 and ivacaftor in people with cystic fibrosis. , protocol number Vertex VX-661-106
This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-661 in combination with ivacaftor in people with CF.
12 Years and Older
11
32 weeks
Phase 3 study of Vertex 661 and ivacaftor in people with CF who have one copy of the F508del-CFTR mutation and a second CFTR mutation predicted to have residual function. , protocol number Vertex NCT02392234 VX14-661-108
This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-661 in combination with ivacaftor and will use a placebo control.
One Copy F508del
12
33 weeks
Phase 3 study of Vertex and ivacaftor in people with cystic fibrosis , protocol number Vertex VX-661-107
25 weeks
Phase 3 study of Vertex 661 and ivacaftor in people with CF who have one copy of the F508del-CFTR mutation and a second CFTR mutation with a gating defect responsive to ivacaftor. , protocol number Vertex VX-661-109
This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-661 in combination with inacaftor and will use a placebo control.
13
Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US
Study of VX-661 plus ivacaftor in people with CF who have two copies of the F508del CFTR mutation. , protocol number NCT02508207 VERTEX VX-661-111
This study evaluated the safety and effectiveness of the CFTR modulator drug VX-661 in combination with ivacaftor (Symdeko®). This study was for people with CF who have two copies of the F508del CFTR mutation.
6
60 days
ObservationalClosed to enrollment Location: USA
An Ocular Safety Study of Kalydeco-Treated Children 11 Years of Age or Younger with CF , protocol number Vertex VX-770-115
This trial is designed to evaluate the risk of of cataracts (lens opacities) and describe the best corrected distance vision (with glasses/contacts for those who wear them) of children with Cystic Fibrosis who are 11 years of age or younger at the time of ivacaftor (Kalydeco) treatment initiation and are receiving or planning to receive commercially-available ivacaftor (Kalydeco) in the US.
6 Years to 11 Years
One Copy F508del or No Copies F50del
No FEV1 Limit
5
2 years
Phase 3 study of lumacaftor and ivacaftor in which cystic fibrosis with advanced lung disease. , protocol number Vertex VX-809-106
This study is taking place at multiple care centers across the U.S. It will evaluate the safety of the drugs lumacaftor and ivacaftor in people with advanced lung disease.
Less than 40%
14
52 weeks
Phase 3 study of lumarcaftor and ivacaftor in children with cystic fibrosis , protocol number Vertex VX-809-109
This study is taking place at multiple care centers across the U.S. It will evaulate the safety and effectiveness of the drugs lumacaftor and ivacaftor in children with cystic fibrosis.
70% to 105%
24 weeks